Send til en ven   Udskriv6/9 2010 kl. 11:51
Send til en ven

Lab-on-chip skal hjælpe cancerdiagnose

Europæisk samarbejde om udvikling af lab-on-chip system til billigere og hurtigere diagnose af cancer (in english). 

At the Engineering in Medicine and Biology Conference (EMBC) in Buenos Aires (Argentina), imec  and its project partners announce the launch of the European Seventh
Framework Project MIRACLE. The MIRACLE project aims at developing an operational lab-on-chip for the isolation and detection of circulating and disseminated tumor cells (CTCs and DTCs) in blood. The new lab-on-chip is an essential step towards faster and cost-efficient diagnosis of cancer.

Detection of circulating and disseminated tumor cells in blood is a promising methodology to diagnose cancer dissemination or to follow up  cancer patients during therapy. Today, the detection analyses of these  cells are performed in medical laboratories requiring labor intensive,  expensive and time-consuming sample processing and cell isolation steps. 


A full tumor cell detection analysis can take more than a day. A  lab-on-chip, integrating the many processing steps, would enable a  faster, easy-to-use, cost-effective detection of tumor cells in blood.  They are therefore labor-saving and minimally invasive, increasing the patient’s comfort and the efficiency of today’s healthcare.

In a preceding joint project by some of the partners (MASCOT FP6-027652), individual microfluidic modules for cell isolation, cell  counting, DNA amplification and detection have been developed. Based on this expertise and strengthened by additional partners, the development of a fully automated, lab-on-chip platform to isolate, count and genotype CTCs is envisaged within the framework of the MIRACLE project.

For genotyping, genetic material (i.e. the mRNA) will be extracted from the cells and multiple cancer related markers will be amplified based on  multiplex ligation dependent probe amplification (MLPA) followed by their detection using an array of electrochemical sensors. Full integration of all steps requires innovative research and processing
steps that need a combination of the multidisciplinary and unique expertise of the different project partners (ranging from microfluidics  to interfacing, miniaturization, and integration skills).

The resulting lab-on-chip tumor detection system will be well ahead of the current
state-of-the-art, revolutionizing cancer diagnostics and individualized theranostics.

Within the framework of the MIRACLE project, imec as project coordinator, collaborates with the Universitat Rovira I Virgili (Spain), the Institut für Mikrotechnik Mainz, AdnaGen, ThinXXs and Consultech (Germany), MRC Holland (The Netherlands), the Oslo University Hospital (Norway), the KTH Royal Institute of Technology, Multi-D and Fujirebio
Diagnostics (Sweden), ECCO - the European CanCer Organisation and  ICsense (Belgium) and Labman (UK). The project aims at developing a fully automated and integrated microsystem providing the genotype (gene expression profile) of CTCs and DTCs starting from clinical samples.

MIRACLE is partly funded by the European Commission (FP7-ICT-2009.3.9). More information on the project is available on the web: www.miracle-fp7.eu

Relaterede nyheder
Elektronik & Data • Odsgard A/S • Stationsparken 25 • 2600 Glostrup • Tlf: +45 4345 1063